NASDAQ:ONTX

Onconova Therapeutics Competitors

$0.71
+0.04 (+6.27 %)
(As of 04/14/2021 01:02 PM ET)
Add
Compare
Today's Range
$0.67
Now: $0.71
$0.73
50-Day Range
$0.72
MA: $1.08
$1.56
52-Week Range
$0.19
Now: $0.71
$1.93
Volume91,527 shs
Average Volume49.09 million shs
Market Capitalization$168.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03

Competitors

Onconova Therapeutics (NASDAQ:ONTX) Vs. ALBO, KDMN, RIGL, RLMD, KDNY, and IDYA

Should you be buying ONTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Onconova Therapeutics, including Albireo Pharma (ALBO), Kadmon (KDMN), Rigel Pharmaceuticals (RIGL), Relmada Therapeutics (RLMD), Chinook Therapeutics (KDNY), and IDEAYA Biosciences (IDYA).

Albireo Pharma (NASDAQ:ALBO) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation & Earnings

This table compares Albireo Pharma and Onconova Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albireo Pharma$9.64 million65.17$-62,720,000.00($5.04)-6.52
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48

Onconova Therapeutics has lower revenue, but higher earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Albireo Pharma has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Albireo Pharma and Onconova Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albireo Pharma00803.00
Onconova Therapeutics03102.25

Albireo Pharma presently has a consensus target price of $72.00, suggesting a potential upside of 118.65%. Onconova Therapeutics has a consensus target price of $1.5167, suggesting a potential upside of 109.48%. Given Albireo Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Albireo Pharma is more favorable than Onconova Therapeutics.

Profitability

This table compares Albireo Pharma and Onconova Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albireo Pharma-751.53%-71.22%-42.91%
Onconova Therapeutics-11,997.55%-161.10%-89.69%

Insider & Institutional Ownership

85.7% of Albireo Pharma shares are owned by institutional investors. Comparatively, 6.7% of Onconova Therapeutics shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by company insiders. Comparatively, 1.8% of Onconova Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Albireo Pharma beats Onconova Therapeutics on 9 of the 14 factors compared between the two stocks.

Kadmon (NASDAQ:KDMN) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares Kadmon and Onconova Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kadmon$5.09 million130.97$-61,370,000.00($0.74)-5.24
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48

Onconova Therapeutics has lower revenue, but higher earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Kadmon and Onconova Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kadmon00503.00
Onconova Therapeutics03102.25

Kadmon presently has a consensus price target of $12.75, suggesting a potential upside of 226.92%. Onconova Therapeutics has a consensus price target of $1.5167, suggesting a potential upside of 109.48%. Given Kadmon's stronger consensus rating and higher possible upside, analysts plainly believe Kadmon is more favorable than Onconova Therapeutics.

Risk and Volatility

Kadmon has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Insider and Institutional Ownership

94.8% of Kadmon shares are held by institutional investors. Comparatively, 6.7% of Onconova Therapeutics shares are held by institutional investors. 3.0% of Kadmon shares are held by insiders. Comparatively, 1.8% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kadmon and Onconova Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kadmon-768.36%-85.07%-46.46%
Onconova Therapeutics-11,997.55%-161.10%-89.69%

Summary

Kadmon beats Onconova Therapeutics on 11 of the 14 factors compared between the two stocks.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and Onconova Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.73$-66,890,000.00($0.40)-9.35
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48

Onconova Therapeutics has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Rigel Pharmaceuticals and Onconova Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Onconova Therapeutics03102.25

Rigel Pharmaceuticals presently has a consensus price target of $8.3333, suggesting a potential upside of 125.84%. Onconova Therapeutics has a consensus price target of $1.5167, suggesting a potential upside of 109.48%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Onconova Therapeutics.

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares Rigel Pharmaceuticals and Onconova Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Onconova Therapeutics-11,997.55%-161.10%-89.69%

Insider & Institutional Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of Onconova Therapeutics shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Onconova Therapeutics on 10 of the 14 factors compared between the two stocks.

Onconova Therapeutics (NASDAQ:ONTX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Institutional & Insider Ownership

6.7% of Onconova Therapeutics shares are held by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are held by institutional investors. 1.8% of Onconova Therapeutics shares are held by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Onconova Therapeutics and Relmada Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48
Relmada TherapeuticsN/AN/AN/A($2.16)-17.22

Relmada Therapeutics has lower revenue, but higher earnings than Onconova Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Onconova Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Onconova Therapeutics and Relmada Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Onconova Therapeutics03102.25
Relmada Therapeutics01202.67

Onconova Therapeutics presently has a consensus target price of $1.5167, indicating a potential upside of 109.48%. Relmada Therapeutics has a consensus target price of $63.3333, indicating a potential upside of 70.30%. Given Onconova Therapeutics' higher probable upside, analysts plainly believe Onconova Therapeutics is more favorable than Relmada Therapeutics.

Profitability

This table compares Onconova Therapeutics and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Onconova Therapeutics-11,997.55%-161.10%-89.69%
Relmada TherapeuticsN/A-32.03%-31.41%

Summary

Relmada Therapeutics beats Onconova Therapeutics on 7 of the 12 factors compared between the two stocks.

Onconova Therapeutics (NASDAQ:ONTX) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Institutional & Insider Ownership

6.7% of Onconova Therapeutics shares are held by institutional investors. 1.8% of Onconova Therapeutics shares are held by company insiders. Comparatively, 5.9% of Chinook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Onconova Therapeutics and Chinook Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Onconova Therapeutics03102.25
Chinook Therapeutics00803.00

Onconova Therapeutics currently has a consensus price target of $1.5167, indicating a potential upside of 109.48%. Chinook Therapeutics has a consensus price target of $30.3333, indicating a potential upside of 117.44%. Given Chinook Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chinook Therapeutics is more favorable than Onconova Therapeutics.

Profitability

This table compares Onconova Therapeutics and Chinook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Onconova Therapeutics-11,997.55%-161.10%-89.69%
Chinook Therapeutics-215.80%-112.72%-21.36%

Volatility & Risk

Onconova Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Valuation & Earnings

This table compares Onconova Therapeutics and Chinook Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48
Chinook Therapeutics$17.26 million34.25$-82,370,000.00($5.15)-2.71

Onconova Therapeutics has higher earnings, but lower revenue than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Chinook Therapeutics beats Onconova Therapeutics on 8 of the 14 factors compared between the two stocks.

IDEAYA Biosciences (NASDAQ:IDYA) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 6.7% of Onconova Therapeutics shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 1.8% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares IDEAYA Biosciences and Onconova Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Onconova Therapeutics-11,997.55%-161.10%-89.69%

Earnings & Valuation

This table compares IDEAYA Biosciences and Onconova Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.57
Onconova Therapeutics$2.18 million77.28$-21,500,000.00($1.49)-0.48

Onconova Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for IDEAYA Biosciences and Onconova Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00603.00
Onconova Therapeutics03102.25

IDEAYA Biosciences currently has a consensus price target of $29.1250, indicating a potential upside of 55.67%. Onconova Therapeutics has a consensus price target of $1.5167, indicating a potential upside of 109.48%. Given Onconova Therapeutics' higher possible upside, analysts clearly believe Onconova Therapeutics is more favorable than IDEAYA Biosciences.

Volatility & Risk

IDEAYA Biosciences has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.

Summary

IDEAYA Biosciences beats Onconova Therapeutics on 8 of the 13 factors compared between the two stocks.


Onconova Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.87+0.9%$622.54 million$9.64 million-5.35News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.88+6.7%$621.98 million$5.09 million-6.47Analyst Downgrade
News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.74+3.5%$614.14 million$59.29 million-24.93Increase in Short Interest
News Coverage
Gap Up
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$37.19+3.3%$602.22 millionN/A-17.22
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.95+0.3%$589.46 million$17.26 million-3.88Analyst Revision
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.71+3.2%$584.23 millionN/A-9.95Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.47+4.5%$561.28 million$8 million-7.92
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.64+3.5%$556.83 million$195.89 million124.69
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.82+4.4%$547.56 millionN/A-5.47Gap Down
Inventiva logo
IVA
Inventiva
0.0$13.75+1.7%$540.43 millionN/A0.00News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.96+1.0%$539.54 million$26.74 million17.40
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.88+4.4%$536.73 millionN/A-9.21Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.39+2.3%$529.13 million$1.19 million-6.83
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.00+3.8%$520.28 millionN/A-4.76
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.07+3.3%$519.55 millionN/A-5.68
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.14+6.5%$517.94 millionN/A-4.36
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.32+0.9%$516.80 million$25 million-18.95Analyst Report
Evolus logo
EOLS
Evolus
1.3$12.02+3.0%$509.93 million$34.92 million-5.92Analyst Report
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.3$8.83+3.3%$499.29 million$59.22 million44.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.24+0.4%$494.53 million$49.65 million-1.74Analyst Upgrade
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.72+0.9%$492.23 million$58.12 million-15.95Decrease in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.6$8.35+7.1%$491.79 millionN/A-5.60Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$17.16+2.8%$491.38 millionN/A1.19
Akouos logo
AKUS
Akouos
1.6$14.69+3.5%$487.82 millionN/A0.00News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$7.03+5.1%$479.82 million$111.75 million-7.81Gap Down
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$22.17+13.0%$479.67 millionN/A-8.73Gap Down
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.27+0.6%$476.23 millionN/A-2.51
Altimmune logo
ALT
Altimmune
1.9$13.20+4.0%$470.69 million$5.80 million-6.63Increase in Short Interest
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.63+2.4%$469.29 million$72.96 million-3.12Analyst Report
News Coverage
Gap Down
89bio logo
ETNB
89bio
1.6$24.58+4.4%$468.93 millionN/A-4.87
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$37.09+6.6%$468.09 million$40,000.00-1.61Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.35+13.3%$467.89 million$36.63 million-5.12News Coverage
Gap Up
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.15+3.8%$465.11 million$335 million-1.06
Verastem logo
VSTM
Verastem
1.3$2.68+0.7%$463.50 million$17.46 million-1.90Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.04+2.6%$455.80 million$109.33 million-2.24Analyst Report
Gap Down
Geron logo
GERN
Geron
1.4$1.53+6.2%$455.50 million$460,000.00-4.36Decrease in Short Interest
News Coverage
Gap Down
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.49+2.4%$454.75 million$102.31 million6.70Increase in Short Interest
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.00+1.8%$449.54 millionN/A0.00News Coverage
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.06+0.2%$447.93 millionN/A0.00News Coverage
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.39+0.2%$446.09 million$56.50 million0.00
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.19+5.0%$442.48 million$57.49 million-6.04Increase in Short Interest
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.54+7.8%$441.13 million$22.27 million-4.19Insider Buying
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.32+2.2%$440.71 million$6.07 million-3.50
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.07+4.2%$438.26 million$6.68 million-4.90News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.02+2.0%$437.39 millionN/A-12.29
BCEL
Atreca
1.7$12.40+6.2%$428.35 millionN/A-4.40News Coverage
Gap Down
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$17.21+4.4%$427.85 millionN/A-3.62Gap Down
XOMA logo
XOMA
XOMA
1.3$37.87+0.9%$422.33 million$18.37 million-34.12Increase in Short Interest
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$33.64+1.8%$408.42 million$206.55 million-16.90Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.